Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Highlights GLP-1 medicines reduce fat and liver mass more rapidly than skeletal muscle (SKM) Running performance is maintained or improved in mice on GLP-1 medicine GLP-1 medicine modifies the SKM proteome despite similar weight loss as calorie restriction Patients on GLP-1 medicine slightly reduce SKM mass but largely maintain strength Summary The large decrease in body weight with glucagon-like peptide-1 (GLP-1) medicines raises concern about a loss of lean body mass (LBM) and skeletal muscle
Clinically, BPC-157 and TB-500 are synergistic
Aim for steady fluid intake
It may also potentially suppress the impact of Somatostatin
While occasional consumption may not drastically affect your levels, regular drinking can counteract the benefits of your supplementation
Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management
